Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia

Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies

(2018) Michael R. Savona et al.   AMERICAN JOURNAL OF HEMATOLOGY

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers

(2018) Michael Seiler et al.   NATURE MEDICINE

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

(2018) Rami Komrokji et al.   Lancet Haematology

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia

(2017) V Santini et al.   LEUKEMIA

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia

(2016) Piyanuch Kongtim et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

(2016) C. Elena et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib inRAS-mutant relapsed or refractory myeloid malignancies

(2016) Gautam Borthakur et al.   CANCER

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

(2016) E. Padron et al.   CLINICAL CANCER RESEARCH

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale

(2016) Hanadi Ramadan et al.   Clinical Lymphoma Myeloma & Leukemia

Allogeneic stem cell transplantation in myelodysplastic syndromes

(2016) Charlotte K. Brierley et al.   CURRENT OPINION IN HEMATOLOGY

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Trans

(2015) Argiris Symeonidis et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

(2015) Jean-Pierre J Issa et al.   LANCET ONCOLOGY

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

(2015) G Garcia-Manero et al.   LEUKEMIA

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies

(2015) E Padron et al.   Blood Cancer Journal

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study

(2014) Emnet A. Wassie et al.   AMERICAN JOURNAL OF HEMATOLOGY

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

(2014) R. Bejar et al.   BLOOD

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients

(2014) M M Patnaik et al.   LEUKEMIA

GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia

(2013) E. Padron et al.   BLOOD

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia

(2013) E. Such et al.   BLOOD

Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis

(2013) John Koreth et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

(2013) Raphaël Itzykson et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

(2013) F Traina et al.   LEUKEMIA

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

(2013) M M Patnaik et al.   LEUKEMIA

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine

(2013) Lionel Adès et al.   LEUKEMIA RESEARCH

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

(2012) Alan F. List et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

(2012) Gandhi Damaj et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of chronic myelomonocytic leukemia with azacitidine

(2012) Eric Wong et al.   LEUKEMIA & LYMPHOMA

High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study

(2012) Luana Fianchi et al.   LEUKEMIA & LYMPHOMA

Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review

(2012) Michael Thorpe et al.   LEUKEMIA RESEARCH

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial

(2011) T. Braun et al.   BLOOD

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities

(2010) Hesham Eissa et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Activity of azacitidine in chronic myelomonocytic leukemia

(2010) Rubens Costa et al.   CANCER

Cytogenetic risk stratification in chronic myelomonocytic leukemia

(2010) E. Such et al.   HAEMATOLOGICA

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

(2010) Paul W. Hollenbach et al.   PLoS One

How I treat patients with myelodysplastic syndromes

(2009) R. M. Stone   BLOOD

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation

(2009) T Field et al.   BONE MARROW TRANSPLANTATION

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

(2008) D. E. Rollison et al.   BLOOD

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

(2008) Hagop Kantarjian et al.   CANCER

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

(2008) Norbert Gattermann   INTERNATIONAL JOURNAL OF HEMATOLOGY

Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)

(2007) P.W. Wijermans et al.   LEUKEMIA RESEARCH